IDEC-C2B8 Antibody Is in Phase III Testing for B-Cell Lymphoma

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 6
Volume 4
Issue 6

SAN DIEGO, Calif--IDEC Pharmaceuticals Corporation has begun a phase III trial of its anti-lymphoma antibody IDEC-C2B8 in patients with relapsed low-grade and follicular non-Hodgkin's lymphomas. The company is developing the agent in collaboration with Genentech, Inc.

SAN DIEGO, Calif--IDEC Pharmaceuticals Corporation has begun aphase III trial of its anti-lymphoma antibody IDEC-C2B8 in patientswith relapsed low-grade and follicular non-Hodgkin's lymphomas.The company is developing the agent in collaboration with Genentech,Inc.

Up to 200 patients in this single-arm, single-agent trial willreceive four weekly infusions of IDEC-C2B8.

The antibody binds to the CD20 antigen, which is expressed onthe surface of mature B cells and B-cell tumors, but not on B-cellprecursors or plasma cells. Host defenses are thus recruited tokill both malignant and normal B cells. After treatment, the normalB cells regenerate from stem cells within months,IDEC said.

Articles in this issue
IDEC-C2B8 Antibody Is in Phase III Testing for B-Cell Lymphoma
Dr. Peters Named Head of the Michigan Cancer Foundation
Broad-Spectrum Sunscreens Block UVA and UVB
Trials of AccuSite Injectable Gel From Matrix Begin in Basal Cell Ca
Outpatient ABMT at Duke Leads to Savings
Russia Is Taking First Steps to Deliver Its Health-Care System Out of Chaos
Algorithm Optimizes Value of CA125 II Screening for Ovarian Ca
Better Ovarian Cancer Outcome With IP Cisplatin
Counseling Must Go Hand in Hand With Genetic Testing for Breast Cancer
Epirubicin Effective But Toxicity Is Increased
Aggressive 16-Week Multidrug Regimen Improves Breast Cancer Survival
Telomerase Appears to Play a Role in Cancer Cell Immortality
Changes in Health-Care Delivery Could Alter System of Medical Ethics
Researchers Seek Pleural Effusions And Tissue to Create MCB Cell Lines
NIH Granted Gene Therapy Patent
Recent Videos
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
It can cause thrombocytopenia and diarrhea, which are generally manageable and not too big a deal.
2 KOLs are featured in this series.
Related Content
The test may help identify patients with microsatellite instability-high colorectal cancer who benefit from nivolumab therapy alone or with ipilimumab.

Idylla CDx MSI Test Earns FDA Approval in MSI-H Colorectal Cancer

Roman Fabbricatore
September 16th 2025
Article

The test may help identify patients with microsatellite instability-high colorectal cancer who benefit from nivolumab therapy alone or with ipilimumab.

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Patients with BRAF fusion papillary thyroid cancer also had clinical benefit with the therapy.

How Does Plixorafenib Compare With Other BRAF-Mutant Thyroid Cancer Agents?

Tim Cortese
September 16th 2025
Article

Data from a phase 1/2a trial showed that plixorafenib-based care achieved a median PFS of 63.9 months in patients with BRAF-altered thyroid cancers.

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Data from the IDeate-Lung01 trial support the potential role that ifinatamab deruxtecan may play in the management of extensive-stage small cell lung cancer.

I-DXd Shows “Impressive” Responses in Extensive-Stage SCLC

Russ Conroy
September 15th 2025
Article

Data from the IDeate-Lung01 trial support the potential role that ifinatamab deruxtecan may play in the management of extensive-stage small cell lung cancer.

While the trial enrolled patients with renal cell carcinoma and ovarian cancer, the component of the trial including those with renal cell carcinoma was discontinued.

The FDA Grants BTD to R-DXd in Pretreated Gynecologic Cancers

Tim Cortese
September 15th 2025
Article

Findings from a phase 1 and the REJOICE-Ovarian01 trials supported the FDA’s decision to grant the designation to R-DXd in those with gynecologic cancers.